肿瘤的主动特异性免疫治疗 (肿瘤疫苗 )是极具吸引力的治疗方法。目前虽已相继建立了一系列在动物模型中被证明有效的细胞瘤苗设计方案 ,但在临床上所取得的疗效大多有限。其中一个重要的原因是人类自发性肿瘤多为低免疫原性 ,因此 ,人们力求发展一种佐剂 ,以增强瘤苗的免疫原 Active tumor-specific immunotherapy (tumor vaccines) is an attractive treatment. Although a series of cell tumor vaccine design programs that have been proven effective in animal models have been established one after another, the clinical efficacy has been limited. One of the important reasons is that human spontaneous tumors are mostly of low immunogenicity. Therefore, people are striving to develop an adjuvant to enhance the immunogenicity of tumor vaccines.